Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced its participation in the European Healthcare Conference held by the investment bank Bryan, Garnier & Co. on November 12-13, 2019, in Paris, France.

Judith Greciet, CEO, and Nicolas Fellmann, CFO of Onxeo, will present the Company at meetings with international investors on Tuesday, November 12, 2019.